more

Iovance Biotherapeutics (IOVA)

(Real Time Quote from BATS)

$12.06 USD

+0.42 (3.61%)

Updated Apr 29, 2024 12:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

FDA Accepts Iovance's (IOVA) BLA Filing for Melanoma Drug

by Zacks Equity Research Published on May 29,2023

The FDA grants priority review to Iovance's (IOVA) filing seeking approval for its lead pipeline candidate in melanoma indication. A decision is expected before November-end.

Iovance (IOVA) Posts Narrower-Than-Expected Loss in Q1

by Zacks Equity Research Published on May 10,2023

Iovance (IOVA) reports Q1 earnings that beat our estimates. The company's acquisition of IL-2 product Proleukin is expected to close in second-quarter 2023.

Why Is Iovance Biotherapeutics (IOVA) Down 9.2% Since Last Earnings Report?

by Zacks Equity Research Published on March 30,2023

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IOVAPositive Net Change

Iovance (IOVA) Completes Rolling BLA Filing for Melanoma Drug

by Zacks Equity Research Published on March 27,2023

Following the completion of Iovance's (IOVA) regulatory filing for its lead candidate in melanoma indication, the FDA has 60 days to determine the acceptability of the BLA for review.

Iovance (IOVA) Q4 Earnings In Line With Estimates, Revenues Nil

by Zacks Equity Research Published on March 01,2023

Iovance (IOVA) reports Q4 earnings in line with our estimates. Management is on track to complete the rolling BLA submission for lifileucel in melanoma before first-quarter 2023 ends.

Drug, Biotech Stocks' Q4 Earnings on Feb 28: NVAX, IOVA & More

by Kinjel Shah Published on February 27,2023

Let us look at four drug and biotech companies, NVAX, IOVA, ALLO, SRPT and FATE, which are gearing up for their earnings release.

pharmaceuticals

Iovance (IOVA) to Buy Clinigen's Cancer Drug, Stock Up 11.6%

by Zacks Equity Research Published on January 24,2023

Iovance (IOVA) to acquire worldwide rights to an IL-2 product already approved by FDA for two cancer indications. The deal is expected to close by first-quarter 2023.

Iovance (IOVA) Extends Timeline for Rolling BLA of Melanoma Drug

by Zacks Equity Research Published on November 21,2022

Post FDA's feedback on lifileucel, Iovance (IOVA) extends its timeline to complete the rolling BLA submission for lifileucel in melanoma. It expects to complete the filing in the first quarter.

Iovance's (IOVA) Q3 Earnings Beat Estimates, Revenues Nil

by Zacks Equity Research Published on November 04,2022

Iovance Biotherapeutics (IOVA) reports a wider-than-expected loss in Q3. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.

Iovance (IOVA) Doses First Patient in TIL Cancer Therapy Study

by Zacks Equity Research Published on October 11,2022

Iovance (IOVA) doses the first patient in phase I/II study evaluating its TIL therapy candidate, IOV-4001, in adults with metastatic melanoma and NSCLC.

medical

Iovance (IOVA) Focuses on Seeking Nod for Melanoma Therapy

by Zacks Equity Research Published on October 05,2022

Iovance (IOVA) is progressing with its pipeline development. Management, after many delays, initiated a rolling BLA filing with the FDA for its lead candidate in metastatic melanoma.

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

by Zacks Equity Research Published on September 05,2022

Sector ETF report for XBI

Iovance (IOVA) Starts Rolling BLA With FDA for Melanoma Therapy

by Zacks Equity Research Published on August 26,2022

Iovance (IOVA) starts a rolling BLA submission with the FDA seeking approval for its lead pipeline candidate in advanced melanoma patients. The filing is expected to be completed by fourth-quarter 2022.

Iovance (IOVA) Q2 Earnings Miss, Lifileucel BLA on Track

by Zacks Equity Research Published on August 05,2022

Iovance Biotherapeutics (IOVA) reports a wider-than-expected second-quarter loss. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

by Zacks Equity Research Published on July 22,2022

Smart Beta ETF report for XBI

Iovance (IOVA) Pipeline Aids Growth Amid Lack of Marketed Drugs

by Zacks Equity Research Published on June 22,2022

Iovance (IOVA) is progressing well with the clinical development of its pipeline candidates. It expects to file a BLA with the FDA, seeking approval for its lead candidate to treat metastatic melanoma, this August.

Iovance (IOVA) Down After Announcing Data From Melanoma Study

by Zacks Equity Research Published on May 27,2022

Results from a cohort of the phase II study evaluating Iovance's (IOVA) melanoma candidate were not as superior as data from another cohort of the same study.

Iovance (IOVA) Q1 Earnings Beat, Lifileucel BLA on Track

by Zacks Equity Research Published on May 06,2022

Iovance Biotherapeutics (IOVA) reports a narrower-than-expected first-quarter loss. The company is on track to file a regulatory submission for lifileucel in melanoma in August 2022.

Iovance (IOVA) Stock Rallies 33% in a Month: Here's Why

by Zacks Equity Research Published on April 08,2022

Iovance (IOVA) to complete the FDA filing for its lead candidate in melanoma by August. It will start a clinical study for its first TALEN-edited TIL therapy for two advanced cancer indications later this year.

Iovance (IOVA) to Seek FDA Nod for Melanoma Therapy in August

by Zacks Equity Research Published on April 06,2022

Iovance (IOVA) expects to complete FDA filing for lifileucel in metastatic melanoma by August 2022. It also intends to start a phase III combo study with lifileucel in melanoma in late 2022.

Iovance (IOVA) to Start Clinical Studies for TIL Therapy

by Zacks Equity Research Published on March 16,2022

Iovance (IOVA) gets FDA nod to start clinical study for IOV-4001, which utilizes the technology licensed from Cellectis. A clinical study in melanoma or NSCLC indication is expected to begin in 2022.

Iovance (IOVA) Announces Wider-Than-Anticipated Q4 Loss

by Zacks Equity Research Published on February 25,2022

Iovance Biotherapeutics' (IOVA) fourth-quarter loss is wider than expected. The company is on track to file regulatory submission for lifileucel in melanoma by first-half 2022.

Iovance (IOVA) Reports Wider-Than-Anticipated Loss in Q3

by Zacks Equity Research Published on November 05,2021

Iovance Biotherapeutics' (IOVA) third-quarter loss is wider than expected. The company is progressing well in terms of development of pipeline candidates.